<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>America’s Restaurants Face a Dilemma: How to Sell Food in the GLP-1 Era — Live Feed</title><link>https://www.live-feeds.com/feed/america-s-restaurants-face-a-dilemma-how-to-sell-food-in-the-glp-1-era</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/america-s-restaurants-face-a-dilemma-how-to-sell-food-in-the-glp-1-era/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>McDonald's invests $8.5 billion as GLP-1 drugs reduce restaurant appetites</title><link>https://www.live-feeds.com/feed/america-s-restaurants-face-a-dilemma-how-to-sell-food-in-the-glp-1-era</link><guid isPermaLink="false">https://www.live-feeds.com/feed/america-s-restaurants-face-a-dilemma-how-to-sell-food-in-the-glp-1-era#u103173</guid><pubDate>Mon, 05 Oct 2026 16:27:16 +0000</pubDate><description>U.S. restaurants are redesigning menus and pricing to combat a sales slump caused by the rise of GLP-1 weight-loss medications. McDonald&amp;#039;s is spending $8.5 billion to overhaul its offerings to prioritize protein and adapt to the GLP-1 era. Other chains have already launched targeted initiatives: Smoothie King introduced a high-protein, fiber-rich menu in 2024, Olive Garden added a Lighter Portions section with downsized entrees, and Chipotle and Shake Shack now offer high-protein or bunless options to attract diners seeking more protein per calorie.Why it mattersGLP-1 medications reduce a</description></item>
</channel></rss>